Stifel Financial Corp Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Stifel Financial Corp cut its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 20.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 40,237 shares of the company’s stock after selling 10,175 shares during the period. Stifel Financial Corp’s holdings in CRISPR Therapeutics were worth $1,890,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC raised its holdings in CRISPR Therapeutics by 1.0% in the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after acquiring an additional 23,075 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of CRISPR Therapeutics by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after purchasing an additional 19,094 shares during the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of CRISPR Therapeutics by 0.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock valued at $34,025,000 after buying an additional 6,635 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in CRISPR Therapeutics in the 2nd quarter worth about $28,625,000. Institutional investors own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on CRSP. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Wednesday, December 11th. Chardan Capital reaffirmed a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $77.93.

CRISPR Therapeutics Stock Up 0.8 %

Shares of NASDAQ:CRSP opened at $40.72 on Friday. CRISPR Therapeutics AG has a fifty-two week low of $39.41 and a fifty-two week high of $91.10. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -14.39 and a beta of 1.62. The firm’s 50-day simple moving average is $48.45 and its 200-day simple moving average is $50.78.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the firm posted ($1.41) earnings per share. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock worth $2,744,179 in the last three months. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.